Wikidata

(Q63012235)

English

Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis

clinical trial

In more languages

Statements

short name
OPTIMUM-LT (English)
0 references
title
Multicenter, Non-comparative Extension to Study AC-058B301, to Investigate the Long-term Safety, Tolerability, and Control of Disease of Ponesimod 20 mg in Subjects With Relapsing Multiple Sclerosis (English)
0 references
medical condition
sclerosis
0 references
multiple sclerosis
0 references
country
Belarus
0 references
Bosnia and Herzegovina
0 references
Bulgaria
0 references
Canada
0 references
Croatia
0 references
Finland
0 references
France
0 references
Georgia
0 references
Germany
0 references
Greece
0 references
Hungary
0 references
Israel
0 references
Italy
0 references
Latvia
0 references
Lithuania
0 references
Mexico
0 references
Poland
0 references
Portugal
0 references
Romania
0 references
Serbia
0 references
Spain
0 references
Sweden
0 references
Turkey
0 references
Ukraine
0 references
United Kingdom
0 references
start time
17 July 2017
0 references
end time
2 April 2022
0 references
number of participants
800
0 references
minimum age
18 year
0 references
maximum age
65 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q63012235&oldid=1857090081"